Induction chemotherapy followed by adjuvant surgery (IC-AS) in patients with stage I-II small cell lung cancer (SCLC)

T. Shibayama, J. Hiyama, H. Ueoka, Masahiro Tabata, Y. Segawa, K. Gemba, A. Matsushita, T. Ohnoshi, M. Harada, A. Andoh, N. Shimizu, S. Hiraki

Research output: Contribution to journalArticle

Abstract

Ten patients with stage I-II SCLC received IC-AS between 1984 and 1993. As induction chemotherapy, COMP-VAN alternating chemotherapy and CAV-PVP hybrid chemotherapy were administered. The former consisted of a 4 drug combination of cyclophosphamide(CPA), vincristine(VCR), methotrexate (MTX) and procarbazine alternated with a 3-drug combination of etoposide (ETP), adriamycin (ADM) and nimustine every 4 weeks. In the latter, a 3 drug combination of CPA, ADM and VCR given on day 1, and a 2 drug combination of ETP and cisplatin on day 8, were repeated every 4 weeks. All the patients had an objective response, including one complete response by induction chemotherapy. Post-operative pathology revealed SCLC in 4 patients, adenocarcinoma in 2 and no tumor (pathological CR) in 4. Four patients relapsed, and a intrathoracic relapse was experienced in only 2 patients. Six patients have died: 3 from relapsing SCLC, 2 from stomach cancer, and 1 from squamous lung cancer, who was salvaged from relapsing SCLC. The median survival time was 27.5 months, and the 3-year survival rate 37.5%. These results indicate that IC-AS is highly effective for stage I-II SCLC and warrant additional studies comparing IC-AS with chemo-radiotherapy.

Original languageEnglish
Pages (from-to)1953-1958
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume22
Issue number13
Publication statusPublished - 1995

Fingerprint

Induction Chemotherapy
Small Cell Lung Carcinoma
Drug Combinations
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Stomach Neoplasms
Nimustine
Procarbazine
Drug Therapy
Methotrexate
Cisplatin
Lung Neoplasms
Adenocarcinoma
Radiotherapy
Survival Rate
Pathology
Recurrence
Survival

Keywords

  • Chemotherapy
  • Small cell lung cancer
  • Surgery

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Induction chemotherapy followed by adjuvant surgery (IC-AS) in patients with stage I-II small cell lung cancer (SCLC). / Shibayama, T.; Hiyama, J.; Ueoka, H.; Tabata, Masahiro; Segawa, Y.; Gemba, K.; Matsushita, A.; Ohnoshi, T.; Harada, M.; Andoh, A.; Shimizu, N.; Hiraki, S.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 22, No. 13, 1995, p. 1953-1958.

Research output: Contribution to journalArticle

Shibayama, T, Hiyama, J, Ueoka, H, Tabata, M, Segawa, Y, Gemba, K, Matsushita, A, Ohnoshi, T, Harada, M, Andoh, A, Shimizu, N & Hiraki, S 1995, 'Induction chemotherapy followed by adjuvant surgery (IC-AS) in patients with stage I-II small cell lung cancer (SCLC)', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 22, no. 13, pp. 1953-1958.
Shibayama, T. ; Hiyama, J. ; Ueoka, H. ; Tabata, Masahiro ; Segawa, Y. ; Gemba, K. ; Matsushita, A. ; Ohnoshi, T. ; Harada, M. ; Andoh, A. ; Shimizu, N. ; Hiraki, S. / Induction chemotherapy followed by adjuvant surgery (IC-AS) in patients with stage I-II small cell lung cancer (SCLC). In: Gan to kagaku ryoho. Cancer & chemotherapy. 1995 ; Vol. 22, No. 13. pp. 1953-1958.
@article{e4a91ff4412241e383129030d87a5369,
title = "Induction chemotherapy followed by adjuvant surgery (IC-AS) in patients with stage I-II small cell lung cancer (SCLC)",
abstract = "Ten patients with stage I-II SCLC received IC-AS between 1984 and 1993. As induction chemotherapy, COMP-VAN alternating chemotherapy and CAV-PVP hybrid chemotherapy were administered. The former consisted of a 4 drug combination of cyclophosphamide(CPA), vincristine(VCR), methotrexate (MTX) and procarbazine alternated with a 3-drug combination of etoposide (ETP), adriamycin (ADM) and nimustine every 4 weeks. In the latter, a 3 drug combination of CPA, ADM and VCR given on day 1, and a 2 drug combination of ETP and cisplatin on day 8, were repeated every 4 weeks. All the patients had an objective response, including one complete response by induction chemotherapy. Post-operative pathology revealed SCLC in 4 patients, adenocarcinoma in 2 and no tumor (pathological CR) in 4. Four patients relapsed, and a intrathoracic relapse was experienced in only 2 patients. Six patients have died: 3 from relapsing SCLC, 2 from stomach cancer, and 1 from squamous lung cancer, who was salvaged from relapsing SCLC. The median survival time was 27.5 months, and the 3-year survival rate 37.5{\%}. These results indicate that IC-AS is highly effective for stage I-II SCLC and warrant additional studies comparing IC-AS with chemo-radiotherapy.",
keywords = "Chemotherapy, Small cell lung cancer, Surgery",
author = "T. Shibayama and J. Hiyama and H. Ueoka and Masahiro Tabata and Y. Segawa and K. Gemba and A. Matsushita and T. Ohnoshi and M. Harada and A. Andoh and N. Shimizu and S. Hiraki",
year = "1995",
language = "English",
volume = "22",
pages = "1953--1958",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "13",

}

TY - JOUR

T1 - Induction chemotherapy followed by adjuvant surgery (IC-AS) in patients with stage I-II small cell lung cancer (SCLC)

AU - Shibayama, T.

AU - Hiyama, J.

AU - Ueoka, H.

AU - Tabata, Masahiro

AU - Segawa, Y.

AU - Gemba, K.

AU - Matsushita, A.

AU - Ohnoshi, T.

AU - Harada, M.

AU - Andoh, A.

AU - Shimizu, N.

AU - Hiraki, S.

PY - 1995

Y1 - 1995

N2 - Ten patients with stage I-II SCLC received IC-AS between 1984 and 1993. As induction chemotherapy, COMP-VAN alternating chemotherapy and CAV-PVP hybrid chemotherapy were administered. The former consisted of a 4 drug combination of cyclophosphamide(CPA), vincristine(VCR), methotrexate (MTX) and procarbazine alternated with a 3-drug combination of etoposide (ETP), adriamycin (ADM) and nimustine every 4 weeks. In the latter, a 3 drug combination of CPA, ADM and VCR given on day 1, and a 2 drug combination of ETP and cisplatin on day 8, were repeated every 4 weeks. All the patients had an objective response, including one complete response by induction chemotherapy. Post-operative pathology revealed SCLC in 4 patients, adenocarcinoma in 2 and no tumor (pathological CR) in 4. Four patients relapsed, and a intrathoracic relapse was experienced in only 2 patients. Six patients have died: 3 from relapsing SCLC, 2 from stomach cancer, and 1 from squamous lung cancer, who was salvaged from relapsing SCLC. The median survival time was 27.5 months, and the 3-year survival rate 37.5%. These results indicate that IC-AS is highly effective for stage I-II SCLC and warrant additional studies comparing IC-AS with chemo-radiotherapy.

AB - Ten patients with stage I-II SCLC received IC-AS between 1984 and 1993. As induction chemotherapy, COMP-VAN alternating chemotherapy and CAV-PVP hybrid chemotherapy were administered. The former consisted of a 4 drug combination of cyclophosphamide(CPA), vincristine(VCR), methotrexate (MTX) and procarbazine alternated with a 3-drug combination of etoposide (ETP), adriamycin (ADM) and nimustine every 4 weeks. In the latter, a 3 drug combination of CPA, ADM and VCR given on day 1, and a 2 drug combination of ETP and cisplatin on day 8, were repeated every 4 weeks. All the patients had an objective response, including one complete response by induction chemotherapy. Post-operative pathology revealed SCLC in 4 patients, adenocarcinoma in 2 and no tumor (pathological CR) in 4. Four patients relapsed, and a intrathoracic relapse was experienced in only 2 patients. Six patients have died: 3 from relapsing SCLC, 2 from stomach cancer, and 1 from squamous lung cancer, who was salvaged from relapsing SCLC. The median survival time was 27.5 months, and the 3-year survival rate 37.5%. These results indicate that IC-AS is highly effective for stage I-II SCLC and warrant additional studies comparing IC-AS with chemo-radiotherapy.

KW - Chemotherapy

KW - Small cell lung cancer

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=0028848495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028848495&partnerID=8YFLogxK

M3 - Article

C2 - 7487126

AN - SCOPUS:0028848495

VL - 22

SP - 1953

EP - 1958

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 13

ER -